INCY Stock
Incyte Corp. Common Stock
—
Price
Daily closes via Alpaca (IEX); today's point is the latest trade.
Key stats
Valuation
P/E (trailing)58.4
Forward P/E15.5
Price / sales3.9
Price / book4.4
EPS (12 mo)$1.88
Beta0.77
Financial health last 12 months
Revenue growth+24.9%
Earnings growth-68.2%
Gross margin93.2%
Net margin+6.7%
Return on equity7.1%
Debt / equity0.01
Hover a figure for what it means.
Analyst ratings Nov 2026 · 35 analysts
Consensus: Buy
Strong buy 9Buy 10
Hold 16Sell 0
Strong sell 0
| Month | Buy | Hold | Sell | Consensus |
|---|---|---|---|---|
| Nov 2026 | 19 | 16 | 0 | Buy |
| Oct 2026 | 18 | 17 | 0 | Buy |
| Sep 2026 | 18 | 17 | 0 | Buy |
| Aug 2026 | 17 | 16 | 0 | Buy |
Latest news
Keith Manchester Sells $54M Of Roivant Sciences Stock After Sharp Run-Up
Benzinga · 2d ago
Should You Pick Vertex Stock Over Its Biotech Rivals?
Yahoo · 3d ago
INCY Wins European Commission Nod For Skin Disease Drug
Yahoo · 4d ago
Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
SeekingAlpha · 4d ago
Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
SeekingAlpha · 5d ago
Headlines from the last 10 days via Finnhub; links open the publisher's article.
Next earnings
No report scheduled in the next 4 months.
Past earnings moves
No tracked reports yet. TradeSphere saves the expected and actual move for every report from Nov 3, 2026 on, for stocks on the Earnings page.